ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,949.17
-0.60%
US Tech 100
20,202.80
-0.71%
다우존스 지수
43,750.86
0.00%
Bitcoin
89,620.54
2.60%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Moderna Inc (MRNA) 시세

Moderna Inc

Moderna Inc (MRNA)

NASDAQ
39.77
-2.37
(-5.62%)
마감 15 11월 6:00AM
15분 지연
39.00
-0.77
( -1.94% )
시간외 단일가: 10:09PM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
39.00
매수가
38.96
매도가
39.05
거래량
124,247
0.00 일간 변동폭 0.00
38.76 52주 범위 170.47
market_cap
14.991B
전일 종가
39.77
개장가
-
최근 거래 시간
2
@
39.05
마지막 거래 시간
22:10:20
재정 규모
-
VWAP
-
평균 볼륨(3m)
6,005,816
발행 주식
384,396,030
배당수익률
-
주가수익률
-3.24
주당순이익(EPS)
-12.26
매출
6.85B
순이익
-4.71B

Moderna Inc 정보

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of ... Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.modernatx.com
본부
Wilmington, Delaware, USA
설립됨
-
Moderna Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker MRNA. The last closing price for Moderna was US$39.77. Over the last year, Moderna shares have traded in a share price range of US$ 38.76 to US$ 170.47.

Moderna currently has 384,396,030 shares in issue. The market capitalisation of Moderna is US$15.29 billion. Moderna has a price to earnings ratio (PE ratio) of -3.24.

Moderna (MRNA) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

약세

순 프리미엄

-675M

Calls / Puts

11.78%

매수 / 매도

92.73%

OTM / ITM

16.49%

Sweeps 비율

0.60%

MRNA 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

13 11월 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

12 11월 2024
Edgar (US Regulatory)

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire PHILADELPHIA, Nov. 8, 2024 New findings showcase the potential of in vivo...

08 11월 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 11월 2024
Edgar (US Regulatory)

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 PR Newswire PHILADELPHIA, Nov. 5, 2024 Pre-clinical data demonstrate robust...

05 11월 2024
PR Newswire (US)

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940...

28 10월 2024
Business Wire

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence PR Newswire CAMBRIDGE, Masss. and LONDON, Oct...

23 10월 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

09 10월 2024
Edgar (US Regulatory)

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA PR Newswire NEW YORK, Oct. 7, 2024 NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The...

07 10월 2024
PR Newswire (US)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-11.42-22.649742165850.4250.938.761215510943.08184048CS
4-15.6-28.571428571454.657.6938.76745113648.94567696CS
12-43.35-52.641165755982.3584.2838.76600581659.60687545CS
26-88.49-69.4093654404127.49170.4738.76500079287.36679052CS
52-35.46-47.622884770374.46170.4738.76464697992.84802494CS
156-192-83.1168831169231376.411838.765237775146.39992507CS
26020.61112.0717781418.39497.1717.689154134146.96548283CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ASSTAsset Entities Inc
US$ 1.12
(73.37%)
3.85M
BENFBeneficient
US$ 2.00
(60.00%)
38M
GREEGreenidge Generation Holdings Inc
US$ 3.80
(53.85%)
15.1M
TCBPTC BioPharm Holdings PLC
US$ 0.98
(51.04%)
10.43M
RBBRBB Bancorp
US$ 35.01
(41.00%)
327
TFFPTFF Pharmaceuticals Inc
US$ 0.4271
(-73.31%)
753.91k
EYENEyenovia Inc
US$ 0.1473
(-56.69%)
1.37M
TSSITSS Inc
 7.49
(-37.48%)
329.1k
PGCPeapack Gladstone Financial Corporation
US$ 25.01
(-31.39%)
26
HSTMHealthStream Inc
US$ 22.00
(-31.31%)
103
ELABElevai Labs Inc
US$ 0.0237
(-9.54%)
48.43M
BENFBeneficient
US$ 2.00
(60.00%)
38M
STISolidion Technology Inc
US$ 0.4676
(33.60%)
33.76M
GREEGreenidge Generation Holdings Inc
US$ 3.80
(53.85%)
15.1M
TCBPTC BioPharm Holdings PLC
US$ 0.98
(51.04%)
10.43M

MRNA Discussion

게시물 보기
axelvento axelvento 8 시간 전
Trump’s latest controversial Cabinet pick could have a huge impact on Americans’ health and lives
https://edition.cnn.com/2024/11/15/politics/trump-rfk-cabinet-pick-american-health-analysis/index.html

the game$$$$$$$
👍️ 1 🤟 1
axelvento axelvento 9 시간 전
RFK Jr. has built a reputation as a vaccine skeptic but has stopped short of adopting the “anti-vaxx” label attributed to him by critics. The former environmental lawyer has said his children are vaccinated and that he does not oppose safe vaccines.

relax$
👍️0
axelvento axelvento 10 시간 전
Kennedy has been one of the country’s most prominent anti-vaccine conspiracy theorists for years and has frequently spread falsehoods about the safety and efficacy of vaccines. Last week, Kennedy said he would “immediately” begin studying vaccine safety and efficacy but promised to not “take vaccines away from anybody.”
👍️0
Bountiful_Harvest Bountiful_Harvest 12 시간 전
Shares of $MRNA and other hot shot stocks in full collapse on news of RFK joining the Trump admin

👍️0
spartex spartex 17 시간 전
Big selling all of a sudden. Sub $40 now. 52 week low.

Appears that Trump will nominate Rfk Jr. to Health and Human Services Admin.

https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617
👍️0
axelvento axelvento 1 일 전
next-
https://www.theguardian.com/society/2024/oct/23/doctors-trial-worlds-first-vaccine-against-vomiting-bug-norovirus
👍️ 3 🔜 1
Vexari Vexari 2 일 전
The majority shareholder of Moderna is?

When you are suffering

They are profiting
👇️ 1 🗑️ 1 🚽 1 🤪 1 🧻 1
axelvento axelvento 3 일 전
https://www.biospace.com/job-trends/biospace-announces-2025-best-places-to-work-in-biopharma
👋 1 👍 1
axelvento axelvento 6 일 전
Jpmorgan Chase & Co ownership in MRNA / Moderna, Inc.
On November 8, 2024 - Jpmorgan Chase & Co filed a 13F-HR form disclosing ownership of 2,227,044 shares of Moderna, Inc. (US:MRNA) valued at $148,833,351 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 12, 2024 disclosing 1,756,708 shares of Moderna, Inc.. This represents a change in shares of 26.77% during the quarter. The current value of the position is $104,292,471 USD.

https://fintel.io/so/us/mrna/jpmorgan-chase-
👍 2
axelvento axelvento 6 일 전
https://www.acsh.org/news/2024/11/07/dont-be-afraid-mrna-vaccines-49111
👍️ 3 🤙 1
axelvento axelvento 6 일 전
Moderna Buys Norwood Campus for $400M

https://bankerandtradesman.com/moderna-buys-norwood-campus-for-400m/#:~:text=Lab%20developer%20Alexandria%20Real%20Estate,core%20properties%20in%20Greater%20Boston.
👍️ 3 😀 1
axelvento axelvento 1 주 전
Moderna (MRNA) Q3 2024 Earnings Call Transcript

https://www.fool.com/earnings/call-transcripts/2024/11/07/moderna-mrna-q3-2024-earnings-call-transcript/
👍️ 4 ✌️ 1
EarningsCentral EarningsCentral 1 주 전
👍️0
axelvento axelvento 1 주 전
MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively
👍️0
axelvento axelvento 3 주 전
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

https://investors.modernatx.com/news/news-details/2024/Merck-and-Moderna-Initiate-Phase-3-Trial-Evaluating-Adjuvant-V940-mRNA-4157-in-Combination-with-KEYTRUDA-pembrolizumab-After-Neoadjuvant-KEYTRUDA-and-Chemotherapy-in-Patients-With-Certain-Types-of-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx


huge news$
👍️ 1 🤑 1
axelvento axelvento 3 주 전
https://www.investing.com/news/company-news/piper-sandler-maintains-overweight-rating-on-moderna-stock-93CH-3680972
👋 1 👍️ 2
axelvento axelvento 3 주 전
20B market cap, 10B in cash, high potential pipeline in 4 therapeutic areas!
👍️ 2 💪 1
axelvento axelvento 3 주 전
Moderna has a whopping 33 million short share interest, but daily volume now a paper-thin 3.7 million

"Highest shorted stock on S&P500"
👍️ 1 🤣 1 ☝️ 1
axelvento axelvento 3 주 전
MRNA December 6th Options Begin Trading

https://www.nasdaq.com/articles/mrna-december-6th-options-begin-trading
👍️0
axelvento axelvento 3 주 전
Moderna’s norovirus vaccine enters Phase III trials in the UK
The firm hopes to file marketing applications in 2026 to have the vaccine approved by health regulators.

https://www.clinicaltrialsarena.com/news/modernas-norovirus-vaccine-enters-phase-iii-trials-in-the-uk/
👍️ 2 🤙 1
Vexari Vexari 3 주 전
Depends

On the road

That they're on
👎️ 1 🗑️ 1 🚽 1 🧻 1 0️⃣ 1
Vexari Vexari 3 주 전
All that is marketed

Is fear based
🌬️ 1 🎃 1 👎️ 1 🕳️ 1 🗑️ 1
gapole gapole 4 주 전
looks like meltdown here. where is the bad news? $53.54
👍️0
Monksdream Monksdream 4 주 전
MRNA new 52. Week low
👍️0
axelvento axelvento 4 주 전
Moderna stock touches 52-week low. bouncer
👍️0
axelvento axelvento 4 주 전
https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial
👍️ 1 ✌️ 1
jondoeuk jondoeuk 4 주 전
I couldn't find a PR or the poster.
👍️0
Vexari Vexari 1 월 전
Unraveling all the Lies of the Covid-19

Psychological Operation
👎️ 2 🗑️ 1 😎 1 🤥 1 🧻 1 0️⃣ 1
axelvento axelvento 1 월 전
$MRNA We are tackling cancer on an individual basis where we can take samples from each patient, understand their cancer, and design a therapy specifically for them

https://www.fastcompany.com/91202048/the-mrna-advantage
👍️ 1 🫨 1 ☝️ 1
tmonkey tmonkey 1 월 전
this one near a bottom-im in------tmonkey
👍️0
axelvento axelvento 1 월 전
https://www.globenewswire.com/news-release/2024/10/04/2958235/0/en/Global-mRNA-Cancer-Vaccine-Clinical-Trial-FDA-Approval-Market-Size-Future-Opportunity-Companies-Insight.html

$MRNA
👍️ 1 🤑 1
axelvento axelvento 1 월 전
Join us on Nov 8, as we, alongside
moderna_
, share promising data on anti-GPC3 in vivo CAR-M therapy for HCC. We'll also present TIP poster for the Ph1 study of anti-HER2 CAR-Monocytes targeting solid tumors.

https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-upcoming-presentations-sitc-2024
👍️ 1 😃 1
axelvento axelvento 1 월 전
back to the 23 November lows bounce spot watching either way to see if holds or breaks.
👍️0
axelvento axelvento 1 월 전
We have put the mescaline to make you feel better-have a good trip$MRNA
👍️ 2 😀 1
axelvento axelvento 1 월 전
With post hoc analysis....
👍️ 2 🤑 1
Vexari Vexari 1 월 전
What's in this dose of Pivotal

How does it affect the immune system

Why not question what is being announced

Instead of grabbing onto it

Hook line and sinker
👎️ 1 🗑️ 1 🤪 1 🧻 1 0️⃣ 1
axelvento axelvento 1 월 전
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403

https://investors.modernatx.com/news/news-details/2024/Moderna-Announces-First-Participant-Dosed-in-Pivotal-Phase-3-Trial-of-Investigational-mRNA-Norovirus-Vaccine-mRNA-1403/default.aspx
👍️ 1 ✌️ 1
axelvento axelvento 1 월 전
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

https://investors.modernatx.com/news/news-details/2024/Moderna-and-Cenra-Healthcare-Enter-Joint-Agreement-to-Promote-Modernas-mRNA-Respiratory-Vaccine-Portfolio-in-Taiwan-Including-COVID-19-Vaccines/default.aspx
👍️0
axelvento axelvento 2 월 전
Multiple key late-stage readouts are on the way as well. Moderna should report phase 3 results for cytomegalovirus (CMV) vaccine mRNA-1647 as early as year-end. It's also on track to begin generating data later this year from pivotal studies of mRNA-3705 and mRNA-3927 targeting metabolic disorders methylmalonic acidemia and propionic acidemia, respectively.
👍️ 2 😝 1
axelvento axelvento 2 월 전
First cancer vaccine may enter the market in 2025. Always keep that in mind
👍️ 1 ✌️ 1
axelvento axelvento 2 월 전
Mr Justice Meade concluded one of the European Moderna patents, labelled EP565, was “invalid”.

But the judge said a different patent, called EP949, was “valid” and was infringed by Pfizer and BioNTech.

https://finance.yahoo.com/news/covid-19-vaccine-patent-legal-123139810.html

full stop$$$$$$$
👋 1 👍️ 1
Vexari Vexari 2 월 전
What happened to the NIH director

So many have yet

To be disclosed
🎃 1 👎️ 1 🕳️ 1 🗑️ 1 🧻 1
axelvento axelvento 2 월 전
https://www.marketbeat.com/instant-alerts/nasdaq-mrna-sec-filing-2024-09-22/
👍️0
axelvento axelvento 2 월 전
With Pfizer hitting a stumbling block, Moderna’s COVID-19/influenza vaccine, mRNA-1083, could be the first such combination vaccine to reach the market. In June, the company posted results from a Phase III trial that showed mRNA-1083 produced a strong immune response against both COVID-19 and influenza. In releasing the results, Moderna also became the first and, due to Pfizer/BioNTech’s struggles, only company to date to post positive Phase III results for a combination COVID-19/influenza vaccine.

https://www.biospace.com/drug-development/5-late-stage-mrna-vaccines-to-watch
👍️ 2 ✌️ 1
DewDiligence DewDiligence 2 월 전
That's a clcikbait article, IMO. NVO's working with a small company who has some expertise in RNA does not make NOVO a competitor of MRNA.
👍️0
axelvento axelvento 2 월 전
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

https://www.fool.com/investing/2024/09/19/novo-nordisk-just-took-a-530-million-step-onto-mod/

$RELAX
👍️0
axelvento axelvento 2 월 전
Buy the Fear, Sell the Greed$$$$$$
👍️0
Vexari Vexari 2 월 전
That is the question

Why does the NIH own half

Of all MRNA injections
👎️ 1 🗑️ 1 🤪 1 🧻 1 0️⃣ 1
axelvento axelvento 2 월 전
I do not know, what do you think? "It has to bounce back"
👍️0
axelvento axelvento 2 월 전
Moderna was getting too big, too fast. "The size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business," said chief executive officer Stéphane Bancel.
This is after -- just last year -- forecasting the launch of as many as 15 new products over the next five years.

THE WRITING IS ON THE WALL

https://www.fool.com/investing/2024/09/14/after-moderna-shocking-news-is-stock-a-buy-or-sell/
👍️ 1 😀 1

최근 히스토리

NASDAQ
MRNA
Moderna
BIT
1GE
GE Aerospace
NYSE
HOG
Harley Davidson
BIT
P1YSJ4
NLBNPIT1YSJ4 20991231 12...
BIT
PEX
Exchange Traded Fund Ubs...
ASX
MTAV
BetaShares Capital
NYSE
CLS
Celestica
NASDAQ
TCMD
Tactile Systems Technology
BIT
P20G95
NLBNPIT20G95 20241220 130
ASX
GPR
Geopacific Resources
NYSE
KOP
Koppers
CSE
GLL
Gallagher Security
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유